The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $34 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $34 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
The Neuroendocrine Tumor Research Foundation elected Todd Gillman as President of its Board of Directors at the January 2022 meeting. Gillman replaces longtime president Joseph Li, MD.
The Neuroendocrine Tumor Research Foundation received a $5 million endowment gift from The Margie and Robert E. Petersen Foundation. This $5 million gift brings NETRF’s 2021 fundraising total to $7.26 million to fund NET research around the globe.
NETRF elects Suzanne Ludlow to its Board of Directors. Suzanne first became involved with NETRF after her late husband Vince’s journey with neuroendocrine cancer. Read more.
The Neuroendocrine Tumor Research Foundation (NETRF) has awarded $2.62 million in grants to advance research aimed at finding new and innovative treatments for neuroendocrine tumors
NETRF is shining a light on its Everlasting Impact Tribute program, which helps families make a larger impact on NET research with a dynamic program that honors their loved ones.
NETRF Annual Report 2019 looks at scientific milestones and educational innovations. It includes stories about some of the people who have supported us to fund more research projects than ever before and offer new ways to learn about NETs.
Results find delays in care and treatment, fear of exposure to COVID-19 The Neuroendocrine Tumor Research Foundation (NETRF) recently surveyed NET patients and caregivers about
NETRF welcomes two leaders to its Board of Directors. Julie Mebane, Partner, Duane Morris, LLP, and Laurie Rains, Senior Vice President, U.S. Retail Services, Convenience and Liquor Channels, Neilsen. Learn how these new Board members hope to help those living with NETs. (MORE)
Research to Advance Neuroendocrine Tumor Treatment The Neuroendocrine Tumor Research Foundation (NETRF) today announced $3.5 million in neuroendocrine tumor (NET) research grants to fund 12
Physicians discuss the basics of NET diagnosis, classification, and progression. Particular attention is paid to the frequency of misdiagnosis. Two patients share their stories of delayed NET diagnosis and treatment due to the misidentification of symptoms.
